This company has been marked as potentially delisted and may not be actively trading. Travere Therapeutics (RTRX) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesTrendsBuy This Stock RTRX vs. MOR, GMTX, CALT, ZYME, CMRX, CDMO, MENS, SBTX, MBX, and RVNCShould you be buying Travere Therapeutics stock or one of its competitors? The main competitors of Travere Therapeutics include MorphoSys (MOR), Gemini Therapeutics (GMTX), Calliditas Therapeutics AB (publ) (CALT), Zymeworks (ZYME), Chimerix (CMRX), Avid Bioservices (CDMO), Jyong Biotech (MENS), Silverback Therapeutics (SBTX), MBX Biosciences (MBX), and Revance Therapeutics (RVNC). Travere Therapeutics vs. Its Competitors MorphoSys Gemini Therapeutics Calliditas Therapeutics AB (publ) Zymeworks Chimerix Avid Bioservices Jyong Biotech Silverback Therapeutics MBX Biosciences Revance Therapeutics MorphoSys (NASDAQ:MOR) and Travere Therapeutics (NASDAQ:RTRX) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, profitability, risk, earnings, institutional ownership, media sentiment, analyst recommendations and dividends. Which has higher valuation & earnings, MOR or RTRX? Travere Therapeutics has lower revenue, but higher earnings than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than Travere Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMorphoSys$238.28M11.99-$205.35M-$3.48-5.45Travere Therapeutics$175.34M4.37-$146.43M-$3.46-4.34 Is MOR or RTRX more profitable? Travere Therapeutics has a net margin of -49.13% compared to MorphoSys' net margin of -226.79%. Travere Therapeutics' return on equity of -36.38% beat MorphoSys' return on equity.Company Net Margins Return on Equity Return on Assets MorphoSys-226.79% -694.31% -22.55% Travere Therapeutics -49.13%-36.38%-14.90% Do insiders and institutionals hold more shares of MOR or RTRX? 18.4% of MorphoSys shares are held by institutional investors. 0.1% of MorphoSys shares are held by insiders. Comparatively, 4.6% of Travere Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has more volatility and risk, MOR or RTRX? MorphoSys has a beta of 1.2, suggesting that its stock price is 20% more volatile than the S&P 500. Comparatively, Travere Therapeutics has a beta of 0.67, suggesting that its stock price is 33% less volatile than the S&P 500. Does the media refer more to MOR or RTRX? In the previous week, MorphoSys had 1 more articles in the media than Travere Therapeutics. MarketBeat recorded 1 mentions for MorphoSys and 0 mentions for Travere Therapeutics. Travere Therapeutics' average media sentiment score of 0.00 beat MorphoSys' score of -0.71 indicating that Travere Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment MorphoSys Negative Travere Therapeutics Neutral SummaryTravere Therapeutics beats MorphoSys on 7 of the 13 factors compared between the two stocks. Get Travere Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RTRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RTRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RTRX vs. The Competition Export to ExcelMetricTravere TherapeuticsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$766.29M$839.47M$5.55B$9.05BDividend YieldN/A4.84%5.24%4.01%P/E Ratio-7.111.1527.6120.23Price / Sales4.37228.55417.23118.52Price / CashN/A23.4436.8958.10Price / Book2.916.328.035.67Net Income-$146.43M-$27.99M$3.18B$249.21M Travere Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RTRXTravere TherapeuticsN/A$15.01+1.1%N/A+89.0%$766.29M$175.34M-7.11221MORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730News CoverageGMTXGemini TherapeuticsN/A$52.96-2.8%N/A+23.2%$2.29BN/A-52.9630CALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180ZYMEZymeworks1.9953 of 5 stars$12.41-1.1%$21.00+69.2%+53.0%$863.45M$93.38M-8.27460Analyst ForecastCMRXChimerix0.6314 of 5 stars$8.54flat$8.53-0.1%N/A$801.09M$212K-9.0990CDMOAvid Bioservices0.6956 of 5 stars$12.50+0.1%$12.25-2.0%+62.3%$799.18M$139.91M-5.23320High Trading VolumeMENSJyong BiotechN/A$8.48-0.2%N/AN/A$644.73MN/A0.0031SBTXSilverback TherapeuticsN/A$17.45-4.1%N/A+81.7%$629.21MN/A-7.2183High Trading VolumeMBXMBX Biosciences3.2606 of 5 stars$11.61+1.8%$37.50+223.0%N/A$388.05MN/A0.0036RVNCRevance Therapeutics2.7653 of 5 stars$3.65flat$8.45+131.5%N/A$381.02M$234.04M-1.89500 Related Companies and Tools Related Companies MorphoSys Alternatives Gemini Therapeutics Alternatives Calliditas Therapeutics AB (publ) Alternatives Zymeworks Alternatives Chimerix Alternatives Avid Bioservices Alternatives Jyong Biotech Alternatives Silverback Therapeutics Alternatives MBX Biosciences Alternatives Revance Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RTRX) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Travere Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Travere Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
